Monthly payouts in 2026 have run $0.102, $0.105, and $0.108, tracking close to the $0.1055 average seen across 2025. That is a meaningful step up from the $0.0865 average in 2024.
Firm Treasury yields could continue to weigh on the metal amid ongoing inflation concerns. Lingering tensions in the Strait of Hormuz could continue to push oil prices up, reinforcing inflation concerns and weighing on bullion.
The iShares Biotechnology ETF is the default large-cap vehicle for the sector. It is market-cap weighted, which concentrates the fund in cash-generative incumbents rather than spreading capital across clinical-stage names.
The iShares U.S. Treasury Bond ETF holds only U.S. Treasury notes and bonds across the maturity curve, providing the cleanest expression of flight-to-quality stability in a single ticker. Credit risk is effectively zero because every holding carries the full faith and credit of the U.S. government.
EMLC holds a broad mix of about 507 bonds issued by emerging market governments, all denominated in local currencies such as the Brazilian real, South African rand, Turkish lira, and Mexican peso. Almost the entire portfolio is sovereign debt at roughly 99 percent, so the fund is essentially a pure government credit exposure.
HYBL attempts to solve the income problem by combining senior loans, high-yield corporate bonds, and debt tranches from U.S. collateralized loan obligations (CLOs). The result is a portfolio with lower duration and lower volatility compared to traditional high-yield funds, while still targeting high current income with monthly distributions.
The fund blends high yield corporate bonds, senior loans, and debt tranches of U.S. collateralized loan obligations (CLOs) into a single actively managed portfolio, aiming to deliver income that beats the broad bond market while keeping volatility lower than any single segment on its own.
